SPDR Dow Jones Industrial Average ETF

SPDR S&P 500 ETF Trust

Invesco QQQ Trust Series 1

TOSHI

TOSHI is trending amid community excitement and increased trading volume, with holders expressing bullish sentiment and anticipating a significant pump. Discussions revolve around key resistance levels and the potential for new all-time highs, with some drawing comparisons to other meme coins. The community highlights its strong support and resilience during market fluctuations, reinforcing confidence in TOSHI's long-term potential.

The SolyCat is a symbol of energy and mystery. Shining like the sun and agile as a feline.  Solycat is here to take over Solana! Inspired by Shiba Inu’s legendary rise on Ethereum, Solycat is the ultimate meme coin designed for Solana’s fast and scalable blockchain.  Our mission is simple: become the top cat of Solana. With bold branding, a vibrant community, and unstoppable momentum, Solycat is ready to dominate. This isn’t just another token—it’s a movement powered by fun, creativity, and the spirit of decentralization.  Join the pride and let’s make history, one paw at a time!

Solycat

Solycat ($SOLYCAT) is trending amid community excitement surrounding its recent listing on Phantom Wallet. Positive sentiment suggests potential gains, with many referring to it as a hidden gem within the Solana ecosystem. The listing appears to be a catalyst for increased attention and discussion.

Syndax Pharmaceuticals, Inc. engages in the development of cancer therapies. Its products include SyndAccess, Revuforj, Niktimvo, and IncyteCARES. The company was founded by Richard A. Heyman, Eckard Weber, Peter Ordentlich, Ronald M. Evans and Michael Downes on October 11, 2005 and is headquartered in New York, NY.

Syndax Pharmaceuticals Inc

Syndax Pharmaceuticals ($SNDX) is trending due to an upcoming FDA decision on their drug Revuforj for a specific type of leukemia, with the community debating the likelihood of approval and its potential impact. Some traders point to the drug's existing approval for a related condition and analysts' price targets while others cite concerns about side effects and market manipulation. Discussions also mention potential competition and buyout scenarios.

The $ROSIE project centers around a unique, AI-powered memecoin inspired by "Rosie the Robot," a beloved character known for her role as a caring, motherly robot in popular culture. The purpose of $ROSIE is twofold: entertainment through an interactive AI feature and social impact via charitable donations.  Users can interact with an AI version of Rosie on the project’s website, where they can ask questions and engage in conversations. The utility of $ROSIE goes beyond typical memecoins by enabling users to donate tokens, which will be directed towards charitable causes supporting mothers. Through this initiative, the project combines the viral appeal of meme tokens with meaningful contributions to social causes, while leveraging AI technology to create a novel user experience.

Rosie the Robot

ROSIE CRYPTO is gaining attention, with community members highlighting its association with Phantom Wallet and anticipating a potential breakout. Discussions suggest optimism around its early-stage momentum and potential as a rising gem within the crypto space. The community is using terms like "moon rush" and "rocket setup" to describe its current trajectory.

An AI x Metaverse Protocol that is building the future of virtual interactions.

Virtual Protocol

Virtual Protocol ($VIRTUAL) is trending amid community discussions about its potential, use cases, and AI agent ecosystem. Recent price movements and listing on Robinhood are sparking bullish sentiment, while some traders express concerns about pump-and-dump dynamics and potential corrections. The focus remains on the utility of AI agents within the Virtuals ecosystem.

PAW Chain has launched the world’s first Layer 3-centric blockchain, enhancing scalability and inter-chain operability across networks. The roadmap features a decentralized exchange, merchant services, and a DAO, all optimized for high-volume, low-cost transactions. Leveraging smart contracts and EVM compatibility, PAW Chain is set to transform digital finance by providing secure, efficient solutions, allowing any project to go multi-chain, underscored by a community-driven governance model and rigorous security standards including regular security audits.

$PAW is trending amidst community excitement surrounding its multi-chain ecosystem and ongoing development, including news about new projects launching and validator updates. Community members express bullish sentiment, focusing on the project's potential for growth and interoperability. Discussions also highlight staking and upcoming partnerships.

Neuphoria Therapeutics, Inc. is a clinical-stage biotechnology company dedicated to developing therapies that address the complex needs of individuals affected by neuropsychiatric disorders. It focuses on developing BNC210, an oral drug designed for the acute treatment of social anxiety disorder (SAD) and the chronic treatment of post-traumatic stress disorder (PTSD) by selectively targeting the a7 nicotinic acetylcholine receptor. The company was founded on December 23, 2024 and is headquartered in Burlington, MA.

Neuphoria Therapeutics Inc.

NEUP is trending due to a significant surge potentially fueled by news of insider buying, a milestone payment from Merck related to their Alzheimer's program, and strong Q3 earnings. The community is actively discussing the low float and potential for a short squeeze, with some speculating about a potential run to double digits. However, some traders caution about potential dilution and the recent failed drug trial.

Bankr is an advanced AI agent focused on simplifying the process of buying and selling digital assets. Bankr was the first AI agent on Farcaster to help you quickly buy all your favorites coins directly in the social. BankrCoin is the official coin of the agent and was deployed by Bankr itself directly in the Farcaster social feed. Fees from swaps go to support BankrCoin. Bankr is available on Farcaster and will soon be launching a private terminal, token recs, and limit orders on Base.

BankrCoin

BankrCoin ($BNKR) is trending due to recent price pumps, leading to community excitement about potentially "dropping a zero."  Many allude to the project's fundamentals, AI integration, and association with the Base network as reasons for optimism.  Traders are closely watching resistance levels, volume, and overall market conditions for potential breakouts.

Solana Street Bets is not just a memecoin; it's a symbol of creativity, humor, and the power of a united community. Inspired by the infamous /wallstreetbets subreddit. Solana Street Bets is here to put respect on the Wall St originated memes in the industry. Solana Street Bets is a decentralized Solana meme coin inspired by the infamous /wallstreetbets subreddit.

SatoshiStreetBets

SatoshiStreetBets ($SSB) is gaining traction, with the community actively discussing its potential and recent developments such as staking and yield farming. The anticipated BitMart listing and upcoming announcements are creating excitement, while some users are highlighting the project's legitimacy and real-world exposure. Community members are debating the coin's utility, with many highlighting it as a potential long-term play in the crypto space.

The most fair distributed and unique memecoin on Solana regarding hairloss cure charity. It focuses on equitable distribution via advanced tech, eliminating biases. What makes it stand out is its dedication to hairloss cure research through charity. Solana offers speed and scalability for seamless operation. This memecoin can draw diverse investors, from crypto enthusiasts to health and charity advocates.

Styro Steve

Styro Steve ($SS) is trending amid discussions around various tokens within the Phantom Wallet ecosystem on Solana. Community members are highlighting new tokens and those showing momentum, with many emphasizing potential gains and encouraging others to "ape in." Several new coins are being mentioned, including $CUTIE, $SLOPANA, $AINAL and $PUPU.

statis crypto Watchlist

Bitcoin

Ethereum

Solana

Ripple

Dogecoin

Cardano

statis IN Watchlist

Nifty 50

Nifty Bank

Reliance Industries Ltd.

Zomato Ltd.

Tata Consultancy Services

Tata Motors Ltd.

HDFC Bank Ltd.

ITC Ltd.

Adani Enterprises Ltd

Axis Bank Ltd

Bajaj Finance Ltd

statis US Watchlist

SPDR S&P 500 ETF

Apple Inc.

Tesla Inc

Microsoft Corporation

NVIDIA Corp

 Hey, I want to invite you to join Stocktwits. It’s the largest global community of active traders. You’ll get access to the real-time market insights, news, discussion and much more! You can sign up using my unique link below 
 


 has invited you to join Stocktwits

Evofem Biosciences&nbsp;Files Preliminary Proxy for Stockholder Approval of the Acquisition by Aditxt&nbsp;Companies Targeting Closing in Fourth Quarter of 2024&nbsp;Mountain View, CA., September 24, 2024 —&nbsp;Aditxt, Inc. (NASDAQ: ADTX) (“Aditxt” or the “Company”), an innovation platform dedicated to accelerating promising health innovations, today announced that its acquisition target,&nbsp;Evofem Biosciences, Inc. (“Evofem”) (OTCQB: EVFM), today filed a&nbsp;<a href="https://app.quotemedia.com/data/downloadFiling?webmasterId=101533&amp;ref=318604913&amp;type=HTML&amp;symbol=EVFM&amp;cdn=aa965ae7d29bd4fb48009ea93f2217c9&amp;companyName=Evofem+Biosciences+Inc.&amp;formType=PRE+14A&amp;dateFiled=2024-09-23">preliminary proxy</a> to seek stockholder approval of transactions contemplated under the Amended and Restated Merger Agreement dated as of July 12, 2024 (the “Merger Agreement”), with Aditxt and Adifem, Inc., a wholly-owned subsidiary of Aditxt (“Adifem”), pursuant to which, and on the terms and subject to the conditions thereof, Adifem will merge with and into Evofem, with Evofem surviving as a wholly owned subsidiary of Aditxt.Assuming the proposal is approved by Evofem stockholders and other closing conditions are met, including but not limited to the Company raising sufficient capital to fund its obligations at closing, the companies are targeting closing the transaction in the fourth quarter of 2024.&nbsp;No assurance can be provided that all of the conditions to closing will be obtained or satisfied or that either of the transactions will ultimately close.&nbsp;About Evofem Biosciences, Inc.Evofem is commercializing innovative products to address unmet needs in women's sexual and reproductive health. The Company's first FDA-approved product,&nbsp;<a href="https://cts.businesswire.com/ct/CT?id=smartlink&amp;url=http%3A%2F%2Fwww.phexxi.com%2F&amp;esheet=54118917&amp;newsitemid=20240909413916&amp;lan=en-US&amp;anchor=Phexxi%26%23174%3B+%28lactic+acid%2C+citric+acid+and+potassium+bitartrate%29&amp;index=1&amp;md5=3e729597ceeb7cf85250cc4e87c1ad26">Phexxi&nbsp;®&nbsp;(lactic acid, citric acid and potassium bitartrate)&nbsp;</a>, is a hormone-free, on-demand prescription contraceptive vaginal gel. It comes in a box of 12 pre-filled applicators and is applied 0-60 minutes before each act of sex.In July 2024, Evofem broadened its commercial offering with the acquisition of&nbsp;<a href="https://cts.businesswire.com/ct/CT?id=smartlink&amp;url=https%3A%2F%2Fwww.solosec.com%2F&amp;esheet=54118917&amp;newsitemid=20240909413916&amp;lan=en-US&amp;anchor=SOLOSEC%26%23174%3B+%28secnidazole%29+2g+oral+granules&amp;index=2&amp;md5=f57d1d7baa215b526187a6b94e5c1456">SOLOSEC® (secnidazole) 2g oral granules&nbsp;</a>, an FDA-approved oral antibiotic for the treatment of two sexual health diseases: bacterial vaginosis (BV), a common vaginal infection in females 12 years of age and older, and trichomoniasis, a common sexually transmitted infection (STI), in people 12 years of age and older. SOLOSEC provides a complete course of therapy in just one dose.&nbsp;Follow us on: LinkedIn:&nbsp;<a href="https://cts.businesswire.com/ct/CT?id=smartlink&amp;url=https%3A%2F%2Fwww.linkedin.com%2Fcompany%2Fevofem%2F&amp;esheet=54118917&amp;newsitemid=20240909413916&amp;lan=en-US&amp;anchor=https%3A%2F%2Fwww.linkedin.com%2Fcompany%2Fevofem&amp;index=3&amp;md5=d02dd9371f079a9ddf3d4b4c14e86d11">https://www.linkedin.com/company/evofem</a> Facebook:&nbsp;<a href="https://cts.businesswire.com/ct/CT?id=smartlink&amp;url=http%3A%2F%2Fwww.facebook.com%2FEvofem&amp;esheet=54118917&amp;newsitemid=20240909413916&amp;lan=en-US&amp;anchor=http%3A%2F%2Fwww.facebook.com%2FEvofem&amp;index=4&amp;md5=7479074d1930b4c67c3da4c67775fd95">http://www.facebook.com/Evofem</a> X (f/k/a Twitter):&nbsp;<a href="https://cts.businesswire.com/ct/CT?id=smartlink&amp;url=https%3A%2F%2Ftwitter.com%2FEvofem&amp;esheet=54118917&amp;newsitemid=20240909413916&amp;lan=en-US&amp;anchor=https%3A%2F%2Fx.com%2FEvofem&amp;index=5&amp;md5=27b4287d506408c08aa627eaa266acdc">https://x.com/Evofem</a>Phexxi&nbsp;®&nbsp;and SOLOSEC&nbsp;®&nbsp;are registered trademarks of Evofem Biosciences, Inc.&nbsp;About Aditxt, Inc.Aditxt, Inc.®&nbsp;is an innovation platform dedicated to accelerating promising health innovations. Aditxt’s ecosystem of research institutions, industry partners, and shareholders collaboratively drives their mission to "Make Promising Innovations Possible Together." The innovation platform is the cornerstone of Aditxt’s strategy, where multiple disciplines drive disruptive growth and address significant societal challenges. Aditxt operates a unique model that democratizes innovation, ensures every stakeholder’s voice is heard and valued, and empowers collective progress.&nbsp;Aditxt currently operates two programs focused on immune health and precision health. The Company plans to introduce two additional programs dedicated to public health and women’s health. For these, Aditxt has entered into an Arrangement Agreement with Appili Therapeutics, Inc. (“Appili”) (TSX: APLI; OTCPink: APLIF), which focuses on infectious diseases, and a Merger Agreement with Evofem. Each program will be designed to function autonomously while collectively advancing Aditxt’s mission of discovering, developing, and deploying innovative health solutions to tackle some of the most urgent health challenges. The closing of each of the transactions with Appili and Evofem is subject to several conditions, including but not limited to approval of the transactions by the respective target shareholders and Aditxt raising sufficient capital to fund its obligations at closing. No assurance can be provided that all of the conditions to closing will be obtained or satisfied or that either of the transactions will ultimately close.For more information,&nbsp;<a href="https://cts.businesswire.com/ct/CT?id=smartlink&amp;url=http%3A%2F%2Fwww.aditxt.com&amp;esheet=54117118&amp;newsitemid=20240904120561&amp;lan=en-US&amp;anchor=www.aditxt.com&amp;index=4&amp;md5=d821cbe54c4f57eac0b1c374c9688090">www.aditxt.com</a>.Follow us on:LinkedIn:&nbsp;<a href="https://www.linkedin.com/company/aditxt">https://www.linkedin.com/company/aditxt</a>&nbsp; Facebook:&nbsp;<a href="https://cts.businesswire.com/ct/CT?id=smartlink&amp;url=https%3A%2F%2Fwww.facebook.com%2Faditxtplatform%2F&amp;esheet=54117118&amp;newsitemid=20240904120561&amp;lan=en-US&amp;anchor=https%3A%2F%2Fwww.facebook.com%2Faditxtplatform%2F&amp;index=6&amp;md5=44180bd3ab05184be51a0d6dec9d979b">https://www.facebook.com/aditxtplatform/</a>&nbsp;Forward-Looking StatementsCertain statements in this press release constitute “forward-looking statements” within the meaning of federal securities laws. Forward-looking statements include statements regarding the Company’s intentions, beliefs, projections, outlook, analyses, or current expectations concerning, among other things, the Company’s ongoing and planned product and business development; the Company’s ability to finance and execute its strategic M&amp;A initiatives; the Company’s ability to obtain the necessary funding and partner to commence clinical trials; the Company’s intellectual property position; the Company’s ability to develop commercial functions; expectations regarding product launch and revenue; the Company’s results of operations, cash needs, spending, financial condition, liquidity, prospects, growth, and strategies; the Company’s ability to raise additional capital; the industry in which the Company operates; and the trends that may affect the industry or the Company. Forward-looking statements are not guarantees of future performance, and actual results may differ materially from those indicated by these forward-looking statements as a result of various important factors, as well as market and other conditions and those risks more fully discussed in the section titled “Risk Factors” in Aditxt’s most recent Annual Report on Form 10-K, as well as discussions of potential risks, uncertainties, and other important factors in the Company’s other filings with the Securities and Exchange Commission. All such statements speak only as of the date made, and the Company undertakes no obligation to update or revise publicly any forward-looking statements, whether as a result of new information, future events or otherwise, except as required by law.&nbsp;Additional Information and Where to Find ItThis communication may be deemed to be solicitation material in respect of the proposed transactions. In connection with the proposed transactions, a proxy statement of Evofem Biosciences, Inc. and other materials will be filed with the SEC. WE URGE INVESTORS TO READ THE PROXY STATEMENT AND THESE OTHER MATERIALS CAREFULLY WHEN THEY BECOME AVAILABLE BECAUSE THEY WILL CONTAIN IMPORTANT INFORMATION ABOUT EVOFEM BIOSCIENCES, INC. AND THE PROPOSED TRANSACTIONS. Investors will be able to obtain free copies of the proxy statement (when available) as well as other filed documents containing information about Evofem Biosciences, Inc. on the SEC’s website at http://www.sec.gov. Free copies of Evofem Biosciences’ SEC filings are also available from Evofem Biosciences, Inc., 7770 Regents Road, Suite 113-618, San Diego, California 92122, Attention: Corporate Secretary.&nbsp;Participants in the SolicitationEvofem Biosciences and its executive officers, directors, other members of management, employees and Evofem Biosciences may be deemed, under SEC rules, to be participants in the solicitation of proxies from Evofem Biosciences’ stockholders with respect to the proposed transactions. Information regarding the executive officers and directors of Evofem Biosciences is set forth in its definitive proxy statement for its special meeting. More detailed information regarding the identity of potential participants, and their direct or indirect interests, by securities holdings or otherwise, will be set forth in the proxy statement and other materials to be filed with the SEC in connection with the proposed transactions.&nbsp;ContactAditxt, Inc.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Mary O’Brien&nbsp;<a href="mailto:Mobrien@aditxt.com">Mobrien@aditxt.com</a>(516) 753-9933

Evofem Biosciences  Files Preliminary Proxy for Stockholder Approval of the Acquisition by Aditxt

Aditxt and Evofem file a preliminary proxy for stockholder approval of their merger, targeting a Q4 2024 closing. The merger aims to expand innovative women’s health solutions.

Aditxt and Evofem Seek Approval for Merger, Closing Expected Q4 2024

Equity

Aditxt and Evofem file for stockholder approval to finalize their merger in Q4 2024. The acquisition will position Evofem as a wholly owned Aditxt subsidiary, enhancing their women’s health portfolio.

Evofem Biosciences, Inc. is a commercial-stage biopharmaceutical company, which develops and commercializes products to women's sexual and reproductive health. Its product includes Phexxi (lactic acid, citric acid and potassium bitartrate), a hormone-free vaginal gel and EVO100, an investigational drug, which is used for urogenital Chlamydia trachomatis and Neisseria gonorrhoeae infection in women. The company was founded in 2007 and is headquartered in San Diego, CA.

Evofem Biosciences Inc

Cut 25 bps

Cut 50+ bps

No change

What will the Fed decide at its October meeting? Polymarket gives a 92% chance of a 25 bps cut. 
 
*Powered by Polymarket

EVFM
Evofem Biosciences Inc

Feed

News

Sentiment

Fundamentals

Info

Latest EVFM News

EVFMEvofem Biosciences Inc